Aug 6, 2026 06:51AM

Aug 6, 2026 06:50AM

Jul 22, 2026 06:50AM

Jul 22, 2026 06:50AM

Jul 22, 2026 06:50AM

Jul 15, 2026 05:11AM

Jul 6, 2026 06:50AM FDA accepts Pharvaris NDA for oral HAE attack treatment deucrictibant

Jul 6, 2026 06:50AM

Jun 15, 2026 06:50AM

Jun 15, 2026 06:50AM

May 12, 2026 04:05PM

May 8, 2026 06:01AM

May 8, 2026 06:00AM

Apr 20, 2026 06:50AM Pharvaris presents safety data on combined deucrictibant formulations

Apr 20, 2026 06:50AM

Apr 2, 2026 06:50AM

Mar 20, 2026 06:51AM

Mar 20, 2026 06:50AM

Mar 11, 2026 06:50AM

Mar 11, 2026 06:50AM

Mar 11, 2026 06:50AM Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Mar 2, 2026 06:55AM

Mar 2, 2026 06:50AM

Jan 12, 2026 06:50AM

Jan 12, 2026 06:50AM

Dec 3, 2025 06:50AM

Dec 3, 2025 06:50AM

Nov 12, 2025 06:50AM Pharvaris Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 10, 2025 06:50AM

Aug 12, 2025 04:05PM

Jul 10, 2025 06:51AM

Jul 10, 2025 06:50AM

Jun 16, 2025 06:50AM

Jun 16, 2025 06:50AM

Jun 2, 2025 06:52AM Pharvaris (PHVS) Presents Data Supporting Ongoing Clinical Development of Deucrictibant

Jun 2, 2025 06:50AM

May 13, 2025 04:05PM

Apr 7, 2025 06:58AM

Apr 1, 2025 06:50AM

Apr 1, 2025 06:50AM

Mar 3, 2025 06:50AM

Mar 3, 2025 06:50AM Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress

Jan 13, 2025 06:52AM

Jan 13, 2025 06:50AM

Nov 13, 2024 04:10PM

Oct 24, 2024 08:00AM

Sep 5, 2024 06:50AM

Sep 5, 2024 06:50AM

Sep 5, 2024 06:50AM Pharvaris Provides Business Update and Expands Development Program for Deucrictibant

Sep 5, 2024 06:49AM

327,949 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All